– USA, CN – Blue Buffalo, the leading natural pet food company, announced today that Amy Schulman joined its Board of Directors. Ms. Schulman is currently the CEO of Arsia Therapeutics Inc., a Venture Partner at Polaris Ventures, and a Senior Lecturer at the Harvard Business School. Until recently, she was the Executive Vice President and General Counsel of Pfizer Inc., as well as the Business Unit Lead of Pfizer’s Consumer Healthcare business.
“Our business, named after our beloved dog Blue whom we lost to cancer, has grown from its humble beginnings in a barn to the leading natural pet food company in the U.S. As we move forward, we’re looking to add new perspectives to our Board to help guide us into the future,” said Bill Bishop, Founder and Chairman of Blue Buffalo. “We are very pleased to welcome Amy to the Board and to the Blue Buffalo family. She understands our mission and unique company culture. She brings a wealth of expertise in health and wellness from her years of counseling companies in the space, as well as being a business leader of large international organizations.”
“I had the pleasure of seeing Amy in action as a business leader while she was at Pfizer. I look forward to her counsel as a Director as we continue to reach more pet parents and feed more pets in the US and around the world,” said Kurt Schmidt, Chief Executive Officer of Blue Buffalo. “Amy’s experience and deep expertise in health and wellness issues for both humans, including babies, and pets will be invaluable.”
“I am excited to join the Board of Blue Buffalo, a real American entrepreneurial success story that has a very passionate consumer following, makes great products and has built a brand that connects with consumers in a very honest and authentic way,” said Ms. Schulman. “Pet parents have a tremendous bond with their pets and want to provide them the best for their wellbeing. Honoring this bond, the team has had tremendous success in building BLUE into one of the biggest pet food brands in only a decade. I look forward to working with the team and guiding them as a director on their exciting journey.”
About Amy Schulman
Ms. Schulman joined Polaris Partners as a Venture Partner in 2014 and assumed the role of Chief Executive Officer of Arsia Therapeutics. She is also a Senior Lecturer on the faculty of Harvard Business School. Prior to these roles, Ms. Schulman served as General Counsel of Pfizer from 2008 to 2013 and saw the company through its $68 billion acquisition of Wyeth. In addition to her role as General Counsel, Ms. Schulman became the President and General Manager of Pfizer’s global infant formula and nutrition business in 2010. After she led the nearly $12 billion sale of that business to Nestle in 2012, she assumed the responsibility for Pfizer’s Consumer Healthcare business. Before joining Pfizer, Ms. Schulman was a partner at DLA Piper, a leading international law firm, where she was also a member of the Board and Executive Policy Committees.
Ms. Schulman’s accomplishments have earned her recognition from leading publications and organizations. In 2013 Fortune magazine named her one of the “50 Most Powerful Women in Business.” That same year, The American Lawyer named her one of the “Top 50 Innovators,” and The National Law Journal named her one of “The 100 Most Influential Lawyers in America.” The American Bar Association honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. A Phi Beta Kappa graduate of Wesleyan University, Ms. Schulman earned her J.D. from Yale Law School in 1989. She serves on the Board of Directors of Alnylam, Bind Therapeutics, The Brookings Institution and Wesleyan University.
About Blue Buffalo
Blue Buffalo, located in Wilton, CT, is the nation’s leading natural pet food company, and provides natural foods and treats for dogs and cats under its BLUE Life Protection Formula, BLUE Wilderness, BLUE Basics and BLUE Freedom lines. Paying tribute to its founding mission, the company, through the Blue Buffalo Foundation for Cancer Research, is also a leading sponsor of pet cancer awareness and of critical studies of pet cancer, health, treatment and nutrition at top veterinary medical schools across the United States.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.